Library · Digestive & liver · Treatment of celiac disease and intestinal permeability
Larazotide Acetate (INN-202)
INN-202, AT-1001, Larazotide
Peptide derived from a cholera toxin component (zonula occludens toxin), developed in the early 2000s to prevent intestinal tight-junction breakdown seen in celiac disease. In late-stage trials as a potential first drug specifically for celiac disease, aiming to reduce gluten-triggered symptoms and gut damage.
Research score 85/100. Reference only, not a dose.
- Gut Health
- Anti-inflammatory
- Healing
- Inflammation Resolution
- US status
- Investigational
- Approval
- Phase 3 Clinical Trial
- Evidence
- Tight junction regulator reducing intestinal permeability ('leaky gut'). Investigational for Celiac disease adjunct therapy.
- Research score
- 85 / 100
- Indication
- Investigational - Celiac Disease
- Origin
- USA
- Source category
- Digestive System
- Status group
- Investigational
Mechanism
Blocks the zonulin receptor PAR2, preventing zonulin-driven disassembly of tight-junction proteins (occludin, claudins, ZO-1), which keeps the gut barrier intact and limits gluten peptides from crossing into tissue, while also reducing MyD88-driven inflammatory signaling.
Safety file
Well tolerated in trials; adverse events (headache, UTI) similar to placebo, and its non-systemic action limits broader toxicity risk.
- Headache
- Nausea
- Urinary tract infection
- Generally well-tolerated in trials